Conventional (Clear Cell) Renal Cell Carcinoma
Arcus Biosciences Advances Promising Kidney Cancer Drug Casdatifan After Gilead Opts Out
Arcus Biosciences, casdatifan, HIF-2a inhibitor, kidney cancer, clear cell renal cell carcinoma (ccRCC), Gilead Sciences, clinical trial data, $150 million stock offering
Personalized Cancer Vaccine Shows Promise in Preventing Recurrence of Advanced Kidney Cancer
personalized cancer vaccine, kidney cancer, clear cell renal cell carcinoma (ccRCC), neoantigen, immunotherapy, cancer recurrence prevention, phase 1 trial